187 related articles for article (PubMed ID: 36111201)
1. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
Krege JH; Gilsenan AW; Komacko JL; Kellier-Steele N
JBMR Plus; 2022 Sep; 6(9):e10665. PubMed ID: 36111201
[TBL] [Abstract][Full Text] [Related]
2. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
4. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.
Elraiyah T; Gionfriddo MR; Murad MH
J Clin Epidemiol; 2015 Jun; 68(6):698-702. PubMed ID: 25766055
[TBL] [Abstract][Full Text] [Related]
7. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
8. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.
Gilsenan A; Midkiff K; Harris D; McQuay L; Hunter S; Kellier-Steele N; Andrews E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1616-1626. PubMed ID: 32894794
[TBL] [Abstract][Full Text] [Related]
9. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study.
Gilsenan A; Harris D; Reynolds M; McSorley D; Midkiff K; Jackson L; Muldavin B; Kellier-Steele N; Andrews E
Osteoporos Int; 2021 Apr; 32(4):645-651. PubMed ID: 33151378
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide in individuals with a prior history of radiation therapy-a case series.
Cheung YM; Hamnvik OR
Arch Osteoporos; 2021 Oct; 16(1):149. PubMed ID: 34608566
[TBL] [Abstract][Full Text] [Related]
11. Present at the beginning: a personal reminiscence on the history of teriparatide.
Marcus R
Osteoporos Int; 2011 Aug; 22(8):2241-8. PubMed ID: 21452026
[TBL] [Abstract][Full Text] [Related]
12. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
Gilsenan A; Harding A; Kellier-Steele N; Harris D; Midkiff K; Andrews E
Osteoporos Int; 2018 Oct; 29(10):2335-2343. PubMed ID: 29978254
[TBL] [Abstract][Full Text] [Related]
13. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.
Bhandari M; Jin L; See K; Burge R; Gilchrist N; Witvrouw R; Krohn KD; Warner MR; Ahmad QI; Mitlak B
Clin Orthop Relat Res; 2016 May; 474(5):1234-44. PubMed ID: 26932738
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
15. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
Poole KE; Treece GM; Pearson RA; Gee AH; Bolognese MA; Brown JP; Goemaere S; Grauer A; Hanley DA; Mautalen C; Recknor C; Yang YC; Rojeski M; Libanati C; Whitmarsh T
J Bone Miner Res; 2022 Feb; 37(2):256-264. PubMed ID: 34738660
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide for severe osteoporosis.
Cappuzzo KA; Delafuente JC
Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
Burch J; Rice S; Yang H; Neilson A; Stirk L; Francis R; Holloway P; Selby P; Craig D
Health Technol Assess; 2014 Feb; 18(11):1-180. PubMed ID: 24534414
[TBL] [Abstract][Full Text] [Related]
20. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]